Microbiota: Dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression

@article{Wood2012MicrobiotaDD,
  title={Microbiota: Dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression},
  author={Natalie J. Wood},
  journal={Nature Reviews Gastroenterology \&Hepatology},
  year={2012},
  volume={9},
  pages={123-123}
}
  • Natalie J. Wood
  • Published 21 February 2012
  • Medicine, Biology
  • Nature Reviews Gastroenterology &Hepatology
Microbiota: Dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression 

Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis

This review will highlight the association between diet, gut microbiota and liver, and how this axis may promote the development of NAFLD progression, discussing potential mechanisms and alterations due to the dysbiosis of gut microbiota.

A new role for inflammasomes: sensing the disturbances in non-alcoholic fatty liver disease

To determine the cause of progression of NAFLD in Metabolic Syndrome, mice were fed a methionine-choline-deficient diet (MCDD) and inflammasomes NLRP6 and NLRP3, and a cytokine, Interleukin-18 (IL-18) were looked at.

Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases

The potential signaling pathways connecting ER stress with inflammation and the interplay between ER stress and inflammation in the pathogenesis of hepatic steatosis, inflammatory bowel diseases and colitis-associated colon cancer are discussed.

From NAFLD to NASH to cirrhosis—new insights into disease mechanisms

This Review focuses on recently uncovered aspects of the genetic, biochemical, immunological and molecular events that are responsible for the development and progression of this highly prevalent and potentially serious disease.

Gut-liver axis: role of inflammasomes.

Lactobacillus rhamnosus GG Protects against Non-Alcoholic Fatty Liver Disease in Mice

It is shown for the first time that LGG protects mice from NAFLD induced by a high-fructose diet, and the underlying mechanisms of protection likely involve an increase of beneficial bacteria, restoration of gut barrier function and subsequent attenuation of liver inflammation and steatosis.

The CF gastrointestinal microbiome: Structure and clinical impact

The gastrointestinal (GI) microbiome is shaped by host diet, immunity, and other physicochemical characteristics of the GI tract, and perturbations such as antibiotic treatments can lead to

Effects of Maresin 1 (MaR1) on Colonic Inflammation and Gut Dysbiosis in Diet-Induced Obese Mice

In conclusion, MaR1 administration ameliorates the inflammatory state in the colonic mucosa and partially compensates changes on gut microbiota caused by obesity.

The intestinal microbiota: its role in health and disease

The present manuscript aims to summarize the current knowledge and provide an overview of the different concepts on how bacteria contribute to health and disease in animal models and—more importantly—humans.

References

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.